

Clinical trials of mTOR inhibitor for advanced breast cancer (metastatic) in all type of patients

TrialResults-center www.trialresultscenter.org

1 add-on to anti HER-2 agent

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------------|
| everolimus + trastuzumab + paclitaxel vs trastuzumab + paclitaxel | | | |
| BOLERO-1 <i>ongoing</i> [NCT00876395] n=NA follow-up: | Everolimus 10 mg daily in combination with paclitaxel 80mg/m ² weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22 versus Placebo of everolimus daily in combination with paclitaxel 80mg/m ² weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22 | patients with HER2+ advanced breast cancer who have not received trastuzumab in the metastatic setting | Parallel groups |
| everolimus + trastuzumab + vinorelbine vs trastuzumab + vinorelbine alone | | | |
| BOLERO-3 , 2014 [NCT01007942] n=284/285 follow-up: | daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m ²) in 3-week cycles versus placebo plus trastuzumab plus vinorelbine, | women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy | Parallel groups double-blind |

References

BOLERO-1, :

Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Li Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. *Lancet Oncol* 2015;16:816-29 [26092818]

BOLERO-3, 2014:

Andr F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 2014;15:580-91 [24742739]

2 combination with endocrine therapy

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| everolimus + exemestane vs capecitabine | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---------------------------------|
| BOLERO-6 (combination) <i>ongoing</i> [NCT01783444] n=NA follow-up: | Everolimus will oral 10 mg (2 5 mg) daily + Exemestane tablets of 25 mg will be taken orally once per day versus Capecitabine, oral 1250 mg/m2 twice daily for 2 weeks followed by one week rest (3-week cycle) | Postmenopausal patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole | |
| everolimus + exemestane vs exemestane alone | | | |
| BOLERO-2 , 2011 [NCT00863655] n=485/239 follow-up: | everolimus and exemestane versus exemestane and placebo | patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both). | Parallel groups double-blind |
| everolimus + letrozole vs letrozole alone | | | |
| BOLERO-4 <i>ongoing</i> [NCT01698918] n=NA follow-up: | - | Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | open-label |
| temsirolimus + letrozole vs letrozole alone | | | |
| HORIZON , 2013 [NCT00083993] n=556/556 follow-up: | oral letrozole 2.5 mg daily/temsirolimus 30 mg daily (5 days every 2 weeks) versus letrozole/placebo | first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer | Parallel groups double-blind |
| everolimus + tamoxifen vs tamoxifen alone | | | |
| TAMRAD , 2012 [NCT01298713] n=54/57 follow-up: | tamoxifen 20 mg/d plus everolimus 10 mg/d versus tamoxifen 20 mg/d alone | postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, AI-resistant mBC | open-label |

References

BOLERO-6 (combination), :

BOLERO-2, 2011:

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahnoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. *N Engl J Med* 2011 Dec 7; [22149876] [10.1056/NEJMoa1109653](https://doi.org/10.1056/NEJMoa1109653)

Beaver JA, Park BH, The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. *Future Oncol* 2012;8:651-7. [22764762] [10.2217/fon.12.49](https://doi.org/10.2217/fon.12.49)

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. *Ann Oncol* 2014 Dec;25:2357-62 [25231953]

BOLERO-4, :

HORIZON, 2013:

Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brinca S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. *J Clin Oncol* 2013;31:195-202 [[23233719](#)]

TAMRAD , 2012:

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spath D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol* 2012;30:2718-24. [[22565002](#)] [10.1200/JCO.2011.39.0708](#)

3 maintenance mTOR inhibitor

| Trial | Treatments | Patients | Trials design and methods |
|---|---|--|---------------------------|
| maintenance everolimus + AI vs AI alone | | | |
| MAIN-A <i>ongoing</i> [NCT02511639] n=NA follow-up: | Maintenance Aromatase Inhibitors (AIs) + Everolimus versus AIs | patients with HR+ metastatic breast cancer and Disease Control After First Line Chemotherapy | |

References

MAIN-A, :

4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.